Get notified when COSM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (worsened) — Material weaknesses persist for a second consecutive year with identical deficiencies and no measurable remediation progress.
Cosmos Health revenue up 20% to $65M, but net loss widens to $19M on credit provisions
Filed April 15, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read
Key Changes
-
high
Net loss widened 18% to $19.1M despite 20% revenue growth, driven by $5.9M in credit-loss provisions including $3.9M full allowance against a related-party loan and $1.4M impairment of Montreal building advances.
MD&A: Credit-Loss Provisions verify on EDGAR → -
high
Company entered U.S. market for first time through Sky Premium Life nutraceuticals, though over 98% of revenue remains international; UAE distributor placed initial 130K-unit order but no additional orders executed as of filing date.
Business: Geographic Expansion verify on EDGAR → -
high
CCX0722 obesity product launch timeline pushed back six months from Q1/Q2 2026 to Q3/Q4 2026, delaying anticipated commercialization of key pipeline asset.
Business: Product Development verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade COSM commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify